TriStar Health Partners

  • Home
  • About
    • TriStar
    • Team
  • News
  • Investment Strategy
    • Investment Strategy
    • Economic Development Fund – TN Investco
  • Portfolio
  • Contact

BioStable Science & Engineering Completes Direct De Novo Application to FDA for the HAART™ 300 Aortic Annuloplasty Device

October 13, 2016 By tstventures2015

BioStable Science & Engineering, Inc. announced today that it has completed a direct de novo application to the U.S. Food and Drug Administration (FDA) for Class II designation of the HAART 300 Aortic Annuloplasty Device. Submission of the de novo request is an important milestone in BioStable’s efforts to bring the potential benefits of valve repair to U.S. patients suffering with aortic valve insufficiency. (read more)

Filed Under: News

Our Portfolio


VIEW MORE

Subscribe to News & Events

Contact Us

Thank you for your interest in TriStar Health Partners. If you have questions or need further information, please contact us!

TriStar Health Partners

3322 West End Ave, Suite 1100 | Nashville, TN 37203
615.515-9880

Copyright © 2023 TriStar Technology Ventures. All rights reserved (CC-licensed photos excepted).